Emergent BioSolutions is preparing for a bioterrorism or pandemic worst-case scenario. The company develops and produces vaccines that treat or protect against infectious diseases and bio-agents. The company supplies BioThrax (the US's only FDA-approved anthrax vaccine) primarily to the US Department of Defense (DOD), Centers for Disease Control (CDC), and the US Department of Health and Human Services (HHS). It is also developing a post-exposure treatment for anthrax. In 2016 the firm spun off its biosciences division, which works on therapies for leukemia and lymphona and vaccines for such infectious diseases as influenza, as the new public company Aptevo Therapeutics.